Devière J, Ojeda Valdes G, Cuevas Herrera L, Closset J, Le Moine O, Eisendrath P, Moreno C, Dugardeyn S, Barea M, de la Torre R, Edmundowicz S, Scott S
Department of Gastroenterology and Hepatopancreatology, ULB, Hôpital Erasme, Route de Lennik 808, B-1070, Brussels, Belgium.
Surg Endosc. 2008 Mar;22(3):589-98. doi: 10.1007/s00464-007-9662-5. Epub 2007 Nov 1.
To evaluate the safety and feasibility in human subjects of a new transoral restrictive procedure for the treatment of obesity.
The protocol was approved by the institutional review boards (IRBs) of both centers involved, and all patients gave informed consent. Patients met established inclusion criteria for bariatric surgery. The TOGa system (Satiety Inc., Palo Alto, CA), a set of transoral endoscopically guided staplers, was used to create a stapled restrictive pouch along the lesser curve of the stomach. Patients were hospitalized overnight for observation and underwent barium upper gastrointestinal (UGI) the next morning. Post procedure, all patients were placed on a liquid diet for 1 month and asked to begin an exercise program. Follow-up was carried out at 1 week and 1, 3, 4, 5, and 6 months.
Twenty one patients were enrolled [17 female, age 43.7 (22-57) years, BMI 43.3 (35-53) kg/m(2)]. Device introduction was completed safely in all patients. There were no serious adverse events (AEs). The most commonly reported procedure or device related adverse events were vomiting, pain, nausea, and transient dysphagia. At 6 month endoscopy, all patients had persistent full or partial stapled sleeves. Gaps in the staple line were evident in 13 patients. Patients lost an average 17.6 pounds at 1 month, 24.5 pounds at three months, and 26.5 pounds at 6 months post-treatment [excess weight loss (EWL) of 16.2%, 22.6%, and 24.4%, respectively].
There is great interest in new procedures for morbid obesity that could offer lower morbidity than current options. Early experience with the TOGa procedure indicates that this transoral approach may be safe and feasible. Further experience with the device and technique should improve anatomic and functional outcomes in the future. Additional studies are underway.
评估一种用于治疗肥胖症的新型经口限制性手术在人体受试者中的安全性和可行性。
该方案经两个参与中心的机构审查委员会(IRB)批准,所有患者均签署了知情同意书。患者符合既定的减肥手术纳入标准。使用TOGa系统(Satiety Inc.,加利福尼亚州帕洛阿尔托),一套经口内镜引导吻合器,沿着胃小弯创建一个吻合器限制性胃囊。患者住院过夜观察,次日上午接受上消化道钡餐检查。术后,所有患者接受1个月的流食饮食,并被要求开始锻炼计划。在1周以及1、3、4、5和6个月进行随访。
共纳入21例患者[17例女性,年龄43.7(22 - 57)岁,体重指数43.3(35 - 53)kg/m²]。所有患者均安全完成器械置入。无严重不良事件(AE)。最常报告的与手术或器械相关的不良事件为呕吐、疼痛、恶心和短暂性吞咽困难。在6个月的内镜检查中,所有患者均有持续的完整或部分吻合器袖带。13例患者的吻合钉线有间隙。治疗后1个月患者平均体重减轻17.6磅,3个月时减轻24.5磅,6个月时减轻26.5磅[超重减轻(EWL)分别为16.2%、22.6%和24.4%]。
对于病态肥胖的新手术方法有很大兴趣,这些方法可能比现有选择具有更低的发病率。TOGa手术的早期经验表明,这种经口方法可能是安全可行的。该器械和技术的进一步经验应能在未来改善解剖和功能结果。正在进行更多研究。